IMMUNE Pharmaceuticals, a developer of monoclonal antibodies, and Yeda, the technology transfer company of the Weizmann Institute of Science, announced a broad collaboration to develop antibody therapeutics focusing on the development of new cancer treatments. IMMUNE Pharmaceuticals, an Israel and US based biopharmaceutical company, focuses on the development of next generation monoclonal antibodies addressing the treatment of cancer and inflammatory diseases.
Related posts
Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023
Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023
Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023
US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Facebook comments